Volume 7.40 | Oct 15

Cord Blood News 7.40 October 15, 2015
Cord Blood News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook   CBN on Twitter
Microenvironmental Interaction between Hypoxia and Endothelial Cells Controls the Migration Ability of Placenta-Derived Mesenchymal Stem Cells via Alpha4 Integrin and Rho Signaling
Investigators aimed to compare the expression of markers related to integrin-mediated signaling in placenta-derived mesenchymal stem cells dependent on hypoxia and co-cultured with human umbilical vein endothelial cells and to evaluate their correlations between migration ability and microenvironmetal factors including hypoxia and endothelial cells. [J Cell Biochem] Abstract
Only One of These Antibodies Will Work for Your Cell Analysis. We Provide Streamlined Solutions that are Reliable and Save You Time
PUBLICATIONS (Ranked by impact factor of the journal)
High-Dose CD20-Targeted Radioimmunotherapy-Based Autologous Transplantation Improves Outcomes for Persistent Mantle Cell Lymphoma
Researchers assessed 162 consecutive patients with mantle cell lymphoma at their center undergoing autologous stem cell transplant following high-dose radioimmunotherapy-based or standard conditioning. [Br J Haematol] Abstract

Comparative Analysis of Human Mesenchymal Stem Cells Derived from Bone Marrow, Placenta and Adipose Tissue as Sources of Cell Therapy
Scientists characterized mesenchymal stem cells from different sources, including human bone marrow, placenta, and adipose tissue, in terms of the phenotype, surface antigen expression, differentiation ability, proteome reference map and blood flow recovery in a hindlimb ischemic disease model. [J Cell Biochem] Abstract

Cerebral Vasculitis in X-Linked Lymphoproliferative Disease Cured by Matched Unrelated Cord Blood Transplant
A nine-year old boy initially presented aged five years with a restrictive joint disease. A diagnosis of X-linked lymphoproliferative disease was made, based on flow cytometric analysis and the identification of a novel mutation in SH2D1A, c.96G>C. He underwent a reduced intensity unrelated umbilical cord blood transplant, but failed to engraft. [J Clin Immunol] Abstract

Optimal Timing of Mesenchymal Stem Cell Therapy for Neonatal Intraventricular Hemorrhage
The authors showed that intraventricular transplantation of human umbilical cord blood-derived mesenchymal stem cells (MSC) significantly attenuated posthemorrhagic hydrocephalus and brain injury after severe intraventricular hemorrhage (IVH) in newborn rat pups. They aimed to optimize the timing of MSC transplantation for severe IVH. [Cell Transplant] Abstract

Cord Blood Processing by a Novel Filtration System
Investigators describe development and characterization of a novel filter device aimed at allowing cord blood processing, using gentle gravity-led flow. [Cell Prolif] Full Article

Mechanism Study for Hypoxia Induced Differentiation of Insulin-Producing Cells from Umbilical Cord Blood-Derived Mesenchymal Stem Cells
Scientists found that hypoxia induced c-MET elevation efficiently initiated the early stage differentiation of insulin-producing cells (IPCs) from mesenchymal stem cells, and hepatocyte growth factor improved the full differentiation of IPCs by inducing the expression of NGN3. [Biochem Biophys Res Commun] Abstract

Outcome of Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma
Researchers evaluated single-institute outcomes of allogeneic hematopoietic stem cell transplantation with a reduced-intensity conditioning regimen consisting of fludarabine and melphalan for multiple myeloma. [Int J Hematol] Abstract

Adenoviral Vector Carrying Glial Cell-Derived Neurotrophic Factor for Direct Gene Therapy in Comparison with Human Umbilical Cord Blood Cell-Mediated Therapy of Spinal Cord Injury in Rat
Investigators examined the efficacy of glial cell-derived neurotrophic factor (GDNF) delivered using an adenoviral vector (AdV-GDNF) and human umbilical cord blood mononuclear cells (UCB-MCs)+AdV-GDNF therapy by conducting behavioral tests on the animals and morphometric studies on the spinal cord, performing immunofluorescence analyses on glial cells, investigating the survival and migration potential of UCB-MCs, and evaluating the expression of the recombinant GDNF gene. [Spinal Cord] Abstract | Press Release

ErythroClear™ for fast red blood cell depletion of small volume fresh or frozen cord blood samples by cord blood banks and cellular therapy labs. See the data!
Placenta: The Forgotten Organ
The authors present an overview of emerging research in placental biology that highlights these themes and the importance of the placenta to fetal and adult health. [Annu Rev Cell Dev Biol] Abstract

Stem Cell Therapies in the Treatment of Diabetic Retinopathy and Keratopathy
Nonproliferative diabetic retinopathy is characterized by multiple degenerative changes that could be potentially corrected by stem cell therapies. Success was reported with adult stem cells (vascular progenitors or adipose stem cells), as well as induced pluripotent stem cells from cord blood. [Exp Biol Med] Abstract

Visit our reviews page to see a complete list of reviews in the cord blood research field.

Perinatal Stem Cell Society 2016
Seattle Genetics Announces Initiation of Phase I/II Clinical Trial of ADCETRIS® (Brentuximab Vedotin) in Combination with Opdivo® (Nivolumab) in Second-Line Hodgkin Lymphoma
Seattle Genetics, Inc. announced that it has initiated a Phase I/II clinical trial of ADCETRIS in combination with Opdivo for patients with relapsed or refractory Hodgkin lymphoma after failure of frontline treatment. [Seattle Genetics, Inc.] Press Release

Bio-Path Holdings Announces Successful Completion of Cohort 7 of Phase Ib Clinical Trial Evaluating Liposomal Grb-2 in Acute Myeloid Leukemia
Bio-Path Holdings, Inc. announced the successful completion of Cohort 7 of its Phase Ib clinical trial evaluating the toxicity of its lead compound, liposomal Grb-2, combined with low-dose cytarabine chemotherapy in patients with advanced acute myeloid leukemia. [Bio-Path Holdings, Inc.] Press Release

From our sponsor:
Learn about mucociliary differentiation of primary bronchial epithelial cells.
Watch the video.
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW Stem Cells: Development & Management
November 30-December 2, 2015
Phitsanulok, Thailand

Visit our events page to see a complete list of events in the cord blood community.
NEW Assistant Member – Cord Blood Transplantation (Fred Hutchinson Cancer Research Center)

Principal Scientist – Hematopoietic Products (STEMCELL Technologies Inc.)

Postdoctoral Fellow – Leukemia Stem Cell Biology (Lund University)

Postdoctoral Positions – Cancer and Developmental Biology (North Carolina Central University)

Assistant Professor – Stem Cell Biology (University of South Carolina)

Postdoctoral Fellow – Computational Biology/Bioinformatics (Princess Margaret Cancer Center)

Postdoctoral Researcher – Epigenetic Modifiers (Van Andel Research Institute)

Postdoctoral Fellow – HMGA Chromatin Remodeling Proteins in Cancer and Stem Cell Biology (Johns Hopkins University School of Medicine)

Postdoctoral Fellow – Immune Reconstitution in Hematopoietic Stem Cell Transplantation (Stanford University)

Research Associate – Leukemia, Stem Cells and Development (Josep Carreras Leukemia Research Institute)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Cord Blood News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Cord Blood News: Archives | Events | Contact Us